Renowned Neurosurgeon Dr. Kevin Foley Appointed to Curiteva’s Board of Directors

HUNTSVILLE, AL / ACCESSWIRE / February 12, 2024 / Curiteva, a privately held manufacturing and technology company announces the appointment of Kevin Foley, MD, to the board of directors. Dr. Foley is a distinguished neurosurgeon, chairman of the Semmes Murphey Neurologic and Spine Institute and a professor of neurosurgery, orthopedic surgery, and biomedical engineering at the University of Tennessee Health Science Center.

Dr. Foley is recognized in the industry as a pioneering inventor and thought leader in the advancement of minimally invasive surgery leading to over 180 issued US Patents and recognition by the American Association of Neurological Surgeons with the Cushing Award for Technical Excellence and Innovation in Neurosurgery. His influence as a board member, lecturer, and professor reaches beyond MIS into disk regeneration, spinal biomechanics, robotics, and advanced materials to revolutionize patient healing and outcomes in spine surgery.

“We are very excited to have Dr. Foley join our board of directors. His lifetime of experience and notable achievements will be invaluable to Curiteva as we continue our trajectory of innovation with our first of its kind platform technology. Dr. Foley has already provided us with significant clinical insights into our groundbreaking Inspire 3D Printed Trabecular PEEK, and we look forward to adding his firsthand experience to the leadership of our company,” commented Chad Falciani, Founder and Chairman.

The Inspire implant is redefining spinal surgery, integrating advanced PEEK technology with additive manufacturing to optimize patient outcomes. This advancement in additive manufacturing is a testament to Curiteva’s ongoing commitment to excellence in the field of spine surgery.

“It’s a privilege to be part of a company that is so committed to transforming patient care with cutting-edge technologies. I am looking forward to working closely with the Curiteva team to drive future advancements,” said Dr. Kevin Foley.

About Curiteva:

Curiteva is a privately held technology and manufacturing company based in Huntsville, AL. Our business is founded on a commitment to building world-class manufacturing, accelerating research and development, maintaining lean operational discipline, and delivering novel technology to meet the evolving needs of our customers and the patients they serve. Curiteva is pioneering 3D printing of Trabecular PEEK implants with a bioactive nano-surface to revolutionize how engineered structures and implant biomaterials accelerate immunomodulation, enhance healing, and improve patient outcomes. For more information, please visit www.curiteva.com

Contact Information

Kristen Kyzer
Director of Business Development
kkyzer@curiteva.com
256.213.1057

SOURCE: Curiteva

View the original press release on newswire.com.

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

1 minute ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

2 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

1 hour ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

2 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

2 hours ago